E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute myocardial infarction |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10053460 |
E.1.2 | Term | Antiplatelet therapy |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Major heart attack occurs as a result of blockage of coronary arteries due to formation of blood clots consisting mainly of sticky blood cells, and as a result can cause extensive damage to the heart muscle and lead to heart failure and death. One of the main treatment goals is to give antiplatelet drugs (drugs that make sticky blood cells less sticky) as soon as possible. The currently used antiplatelet agents include oral Aspirin in addition to oral Ticagrelor. It is known that patients with major heart attack have reduced absorption from the stomach.Low blood pressure and diversion of blood away from the stomach during a major heart attack reduce absorption and therefore, oral antiplatelet agents are poorly absorbed and have little effect at the time of most need. In this study we aim to demonstrate whether the newer fast acting intravenous Cangrelor has a better antiplatelet effect than the currently used oral Ticagrelor in patients with major heart attacks (STEMI) prior to primar |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1)Patients presenting with STEMI eligible for PPCI 2)Able to give verbal assent pre procedure and written consent following the procedure. 3)Age ≥18 years 4)No contraindication to Cangrelor or Ticagrelor 5)Thienopyridine naïve
If a patient gives verbal assent but is unable to provide a written consent at a later stage due to incapacitation, presumed consent will be continued. The reasons why a patient becomes incapacitated and becomes unable to provide a written consent will be recorded during data collection.
|
|
E.4 | Principal exclusion criteria |
1)Be unable to provide verbal assent and written consent 2)Allergic to Aspirin or any of the P2Y12 antagonists in the trial 3)Have pre-existing cardiogenic shock 4)Previous myocardial infarction 5)Have a concurrent septic or inflammatory disease e.g. rheumatoid arthritis, lupus, and pneumonia. 6)Already taking a P2Y12 inhibitor 7)Known bleeding diathesis 8)Significant active bleeding 9)History of intracranial hemorrhage 10)Patients who are being treated with formal anticoagulation (Vitamin K antagonist, Factor II or Xa inhibitors) or have an indication for anticoagulation during the first four hours of the study period. Example is patients known to have atrial fibrillation, pulmonary embolism or deep vein thrombosis. 11)Known severe renal dysfunction requiring renal replacement therapy.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
We will assess the two drug therapies (Oral Ticagrelor and intravenous Cangrelor) by looking at
•The effect of the drugs on blood platelet “stickiness” using VerifyNow and VASP assays from blood samples taken at the time of first coronary balloon inflation, 4 hours post drug loading and 24-36 hours post drug loading. •The effect on the patency of the treated coronary artery as measured by TIMI Flow Grade done immediately post PPCI. •The effect on the flow in the capillary blood vessels in the heart muscle (Index of Microcirculatory Resistance, IMR) using an intracoronary pressure wire performed after treating the culprit vessel. •ECG recording to assess for degree of ST-segment resolution 90 minutes post PPCI. •The effect on the initial degree of heart muscle damage (via a routine blood test to assess troponin levels undertaken 24-36 hours post PPCI). •The effect on the final degree of heart muscle damage using a Cardiac MRI scan performed at 3 months post PPCI.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Blood sampling for P2Y12 inhibition estimation (using VASP phosphorylation and VerifyNow tests) will be undertaken at the time of first intracoronary balloon inflation, 4 hours post dosing and 24-36 hours post dosing (including troponin levels ).
IMR assessment will be undertaken at the end of the primary PCI.
Flow TIMI Grade assessment will be performed immediately following primary PCI.
An ECG will be recorded within 90 minutes post PCI.
Cardiac MRI Scan will be undertaken three months post primary PCI.
|
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the study will be marked by the last patient’s last visit samples when they have been analysed. The data will then be scrutinised, and finally an article summarising the study written and submitted to a peer-reviewed journal for consideration of publication. Positive trial results might lead to implementation of the use of intravenous Cangrelor in clinical practice. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 1 |